Work

Gα11 mutation in mice causes hypocalcemia rectifiable by calcilytic therapy

Year: 2017
Type: article
Abstract: Heterozygous germline gain-of-function mutations of G-protein subunit α 11 (Gα 11 ), a signaling partner for the calcium-sensing receptor (CaSR), result in autosomal dominant hypocalcemia type 2 (ADH2). ADH2 may cause symptomatic hypocalcemia with low circulating parathyroid hormone (PTH) concentrations. Effective therapies for ADH2 are currently not available, and a mouse model for ADH2 would help in assessment of potential therapies. We hypothesized that a previously reported dark skin mouse mutant ( Dsk7 ) — which has a germline hypermorphic Gα 11 mutation, Ile62Val — may be a model for ADH2 and allow evaluation of calcilytics, which are CaSR negative allosteric modulators, as a targeted therapy for this disorder. Mutant Dsk7/+ and Dsk7/Dsk7 mice were shown to have hypocalcemia and reduced plasma PTH concentrations, similar to ADH2 patients. In vitro studies showed the mutant Val62 Gα 11 to upregulate CaSR-mediated intracellular calcium and MAPK signaling, consistent with a gain of function. Treatment with NPS-2143, a calcilytic compound, normalized these signaling responses. In vivo, NPS-2143 induced a rapid and marked rise in plasma PTH and calcium concentrations in Dsk7/Dsk7 and Dsk7/+ mice, which became normocalcemic. Thus, these studies have established Dsk7 mice, which harbor a germline gain-of-function Gα 11 mutation, as a model for ADH2 and have demonstrated calcilytics as a potential targeted therapy.
Source: JCI Insight
Language: English
Subfield: Nephrology
Field: Medicine
Open Access status: gold
Estimated APC paid: $4,096
OpenAlex ID: W2587753722
FWCI: 11.02
Cites: 47
Cited by: 70
Related to: 10
Parts: 1